{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:21:00Z","timestamp":1793388060683,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Chimeric antigen receptor (CAR)\u2013engineered T-cell therapy is becoming one of the most promising approaches in the treatment of cancer. On June 28, 2018, the Committee for Advanced Therapies (CAT) and the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kymriah for pediatric and young adult patients up to 25\u2009years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse after transplant, or in second or later relapse and for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Kymriah became one of the first European Union\u2013approved CAR T therapies. The active substance of Kymriah is tisagenlecleucel, an autologous, immunocellular cancer therapy that involves reprogramming the patient's own T cells to identify and eliminate CD19-expressing cells. This is achieved by addition of a transgene encoding a CAR. The benefit of Kymriah was its ability to achieve remission with a significant duration in patients with ALL and an objective response with a significant duration in patients with DLBCL. The most common hematological toxicity was cytopenia in both patients with ALL and those with DLBCL. Nonhematological side effects in patients with ALL were cytokine release syndrome (CRS), infections, secondary hypogammaglobulinemia due to B-cell aplasia, pyrexia, and decreased appetite. The most common nonhematological side effects in patients with DLBCL were CRS, infections, pyrexia, diarrhea, nausea, hypotension, and fatigue. Kymriah also received an orphan designation on April 29, 2014, following a positive recommendation by the Committee for Orphan Medicinal Products (COMP). Maintenance of the orphan designation was recommended at the time of marketing authorization as the COMP considered the product was of significant benefit for patients with both conditions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0233","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T18:25:21Z","timestamp":1571250321000},"page":"e321-e327","source":"Crossref","is-referenced-by-count":134,"title":["The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma"],"prefix":"10.1093","volume":"25","author":[{"given":"Sahra","family":"Ali","sequence":"first","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Kjeken","sequence":"additional","affiliation":[{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Niederlaender","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Markey","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese S.","family":"Saunders","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Opsata","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Moltu","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Bremnes","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Gr\u00f8nevik","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Muusse","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro D.","family":"H\u00e5konsen","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venke","family":"Skibeli","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabeth","family":"Kalland","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Wang","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingebj\u00f8rg","family":"Buajordet","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Urbaniak","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Norwegian Medicines Agency, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Johnston","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Rantell","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Kerwash","sequence":"additional","affiliation":[{"name":"Medicines and Healthcare Products Regulatory Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schuessler-Lenz","sequence":"additional","affiliation":[{"name":"Committee for Advanced Therapies, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Salmonson","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Medical Products Agency, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[{"name":"Scientific Advisory Group, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Karolinska University Hospital BioClinicum, New Karolinska Hospital, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"Scientific Advisory Group, European Medicines Agency, Amsterdam, The Netherlands"},{"name":"Institut d'H\u00e9matologie, H\u00f4pital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Tzogani","sequence":"additional","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Papadouli","sequence":"additional","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2021122510121854400_R1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122510121854400_R2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"M\u00f6ricke","year":"2010","journal-title":"Leukemia"},{"key":"2021122510121854400_R3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"2021122510121854400_R4","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122510121854400_R5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(08)70229-8","article-title":"Bone-marrow relapse in paediatric acute lymphoblastic leukaemia","volume":"9","author":"Bailey","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122510121854400_R6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1182\/blood.V91.5.1716.1716_1716_1722","article-title":"TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-M\u00fcnster Study Group","volume":"91","author":"Seeger","year":"1998","journal-title":"Blood"},{"key":"2021122510121854400_R7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"suppl 5","key":"2021122510121854400_R8","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122510121854400_R9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122510121854400_R10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure - what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122510121854400_R11","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122510121854400_R12","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510121854400_R13","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122510121854400_R14","doi-asserted-by":"crossref","first-page":"1684A","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood"},{"key":"2021122510121854400_R15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122510121854400_R16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122510121854400_R17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: A measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2021122510121854400_R18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510121854400_R19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2021122510121854400_R20","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e321\/41918964\/oncolo_25_2_e321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/e321\/41918964\/oncolo_25_2_e321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:13:09Z","timestamp":1640427189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/e321\/6443357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,16]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0233","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,16]]}}}